Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention

  • Pfeffer B
  • Tziros C
  • Katz R
  • 11

    Readers

    Mendeley users who have this article in their library.
  • 15

    Citations

    Citations of this article.

Abstract

A nthracyclines are commonly used antineoplastic drugs. However, their clinical utility is tempered by a dose-dependent risk of cardiotoxicity and congestive heart failure. Current preventive measures focus on dose reduction, use of less cardiotoxic anthracycline analogues and prophylactic use of dexrazoxane. Recent research has focused on early monitoring and risk stratification to identify patients that are 'at risk' for cardiotoxicity, using biochemical markers and the prophylactic use of novel cardioprotectants. This article reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing anthracycline cardiotoxicity.

Author-supplied keywords

  • Anthracycline
  • Cardiotoxicity
  • Chemotherapy
  • Congestive heart failure

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • SCOPUS: 2-s2.0-65249176217
  • ISSN: 09696113
  • SGR: 65249176217
  • PUI: 354493351

Authors

  • Brad Pfeffer

  • Constantine Tziros

  • Richard J. Katz

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free